Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 6/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 1057 Cr | 7637 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.23% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 45 | 39 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.93%) Cipla Ltd (6.19%) Dr Reddy's Laboratories Ltd (4.57%) Ajanta Pharma Ltd (4.43%) Glenmark Pharmaceuticals Ltd (3.74%) | Sun Pharmaceuticals Industries Ltd (13.68%) Divi's Laboratories Ltd (9.32%) Lupin Ltd (7.73%) Cipla Ltd (5.9%) Dr Reddy's Laboratories Ltd (5.35%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.66%) Basic Materials (1.34%) | Health (100%) | ||
Equity % | 99.55% | 98.89% | ||
Debt % | - | - | ||
P/E | 34.67 | 35.31 | ||
P/B | 5.43 | 5.8 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 6.66% | 5.01% | ||
3-Month Return | -9.76% | -10.25% | ||
6-Month Return | -8.63% | -8.83% | ||
1-Year Return | 18.18% | 10.26% | ||
3-Year Return | 20.13% | 18.79% | ||
5-Year Return | 28.62% | 28.6% |
Sharpe | 0.84 | 0.81 | ||
Alpha | 1.26 | 0.8 | ||
Beta | 0.96 | 0.91 | ||
Standard Deviation | 16.7 | 15.85 | ||
Information Ratio | 0.31 | -0.04 |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Kinjal Desai,Sailesh Raj Bhan |